Quick Answer
Telix Pharmaceuticals Ltd reported Total Assets of $1.16 billion for fiscal year 2025.
Telix Pharmaceuticals Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $1.16B +23.8% |
$940.38M +239.2% |
$277.26M | — |
| R&D Expense | $171.25M +33.9% |
$127.93M +50.0% |
$85.31M +5.7% |
$80.69M |
| Gross Profit | $426.44M +26.9% |
$336.16M +60.4% |
$209.53M +120.7% |
$94.93M |
- Telix Pharmaceuticals Ltd reported Total Assets of $1.16 billion for fiscal year 2025.
- Telix Pharmaceuticals Ltd showed an increase of +23.8% in Total Assets compared to the prior fiscal year.
- Telix Pharmaceuticals Ltd reported R&D Expense of $171.25 million for fiscal year 2025.
- Telix Pharmaceuticals Ltd showed an increase of +33.9% in R&D Expense compared to the prior fiscal year.
- Telix Pharmaceuticals Ltd reported Gross Profit of $426.44 million for fiscal year 2025.
- Telix Pharmaceuticals Ltd showed an increase of +26.9% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: